Published online ahead of print in the journal Oncogene , a study led by Josep Villanueva, an Investigator at the Vall d’Hebron Institute of Oncology (VHIO), shows that the receptor for advanced glycation end-product (RAGE) plays a key role in cellular mechanisms of plasticity in mesenchymal triple-negative breast cancer (TNBC) that transform epithelial cells into mesenchymal cells as potent drivers of cancer cell proliferation and tumor invasion.
Medacta Group SA revenues up +19.5% at constant currency1 exceeding the milestone of 500Mln € in FY 2023 – Biotech Investments
Medacta Group SA / Key word(s): Sales Result 02-Feb-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer
February 3, 2024